PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
The PGV001 platform is feasible, safe, and immunogenic. The OpenVax pipeline predicted immunogenic neoantigens in tumors with wide-ranging mutational burdens. Data from this study prompted three additional PGV001 trials, one in newly diagnosed glioblastoma, one in urothelial cancer in combination with an ICI, and another in prostate cancer.
Authors
- John Mandeli (ORCID: https://orcid.org/0000-0001-6955-6160)
- Jeff Hammerbacher (ORCID: https://orcid.org/0000-0001-6596-8563)
- Marcia Meseck (ORCID: https://orcid.org/0000-0002-9527-6602)
- Deborah B. Doroshow (ORCID: https://orcid.org/0000-0002-2221-9818)
- Matthew D. Galsky (ORCID: https://orcid.org/0000-0001-7655-9378)
- Kevin Tuballes (ORCID: https://orcid.org/0000-0002-5899-7080)
- Philip Friedlander (ORCID: https://orcid.org/0000-0001-6538-1615)
- Samir Sunil Parekh (ORCID: https://orcid.org/0000-0001-9694-8469)
- John P. Finnigan (ORCID: https://orcid.org/0000-0003-3216-298X)
- Krzysztof J. Misiukiewicz (ORCID: https://orcid.org/0000-0001-9500-1484)
- Anna Kaminska (ORCID: https://orcid.org/0000-0002-9369-7083)
- Julia Kodysh (ORCID: https://orcid.org/0000-0002-1009-1984)
- Denise Rodriguez
- Ana Acuña-Villaorduña (ORCID: https://orcid.org/0000-0003-0180-2972)
- Nina Bhardwaj (ORCID: https://orcid.org/0000-0003-1865-4187)
- Ana Blasquez
- Sayali Onkar (ORCID: https://orcid.org/0000-0002-5890-290X)
- Ruiwei Guo (ORCID: https://orcid.org/0000-0002-6978-8735)
- Thomas U. Marron (ORCID: https://orcid.org/0000-0001-5903-8191)
- Hanna Y. Irie (ORCID: https://orcid.org/0000-0001-5288-7318)
- Cansu Cimen Bozkus (ORCID: https://orcid.org/0000-0001-7834-4792)
- Eric E. Schadt (ORCID: https://orcid.org/0000-0002-7892-8808)
- Rachel Lubong. Sabado
- Alex Rubinsteyn (ORCID: https://orcid.org/0000-0003-2839-2870)
- Robert Sebra (ORCID: https://orcid.org/0000-0001-9267-2426)
- Sacha Gnjatic (ORCID: https://orcid.org/0000-0001-5643-9520)
- Amy Tiersten (ORCID: https://orcid.org/0000-0002-4054-9140)
- Mesude Bicak (ORCID: https://orcid.org/0000-0002-4546-9801)
- Brett A. Miles
- Rachel Brody (ORCID: https://orcid.org/0000-0001-9280-517X)
- Gustavo Giménez
- Timothy J. O’Donnell
- Marshall R. Posner (ORCID: https://orcid.org/0000-0003-1912-3281)
- Mansi Saxena (ORCID: https://orcid.org/0000-0001-5482-3158)
- Andrea Wolf
- Andres Μ. Salazar (ORCID: https://orcid.org/0000-0003-1723-691X)
- Daniela Delbeau-Zagelbaum
Institutions
- University of North Carolina at Chapel Hill (US)
- Northwell Health (US)
- Regeneron (United States) (US)
- Tampa General Hospital (US)
- Mount Sinai Hospital (US)
- Parker Institute for Cancer Immunotherapy (US)
- Northwell Health Orthopaedic Institute (US)
- Tisch Hospital (US)
- Winchester Medical Center (US)
- Oncovir (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1158/2159-8290.cd-24-0934
- Citations
- 16
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 12.76